The Readout Loud

336 Episodes

1. 294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

   Published: 2/15/2024
2. 293: AI in medicine, detangling hype, and Icelandic DNA

   Published: 2/8/2024
3. 292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

   Published: 2/1/2024
4. 291: The plight of the VC, Gilead's latest setback, & more M&A

   Published: 1/25/2024
5. 290: Biotech layoffs, slumping stocks, and a 2024 preview

   Published: 1/18/2024
6. 289: Live! From #JPM24

   Published: 1/11/2024
7. 287: 2023 in review, CEO report cards, and a look at the year ahead

   Published: 12/21/2023
8. 286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future

   Published: 12/14/2023
9. 285: CRISPR history, biotech struggles, & a big week for deals

   Published: 12/7/2023
10. 284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

    Published: 11/30/2023
11. 283: A CRISPR milestone, algorithms amok, & biotech mixology

    Published: 11/16/2023
12. From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?

    Published: 11/13/2023
13. 282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

    Published: 11/9/2023
14. 281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

    Published: 11/2/2023
15. 280: ESMO highlights, Roivant's big deal, & biotech VC on the rise

    Published: 10/26/2023
16. 279: Live from the 2023 STAT Summit

    Published: 10/19/2023
17. 278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

    Published: 10/12/2023
18. 277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus

    Published: 10/5/2023
19. 276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump

    Published: 9/28/2023
20. 275: A thorny ALS debate at the FDA, and the promise of artificial wombs

    Published: 9/21/2023